1 **Title:** Seroprevalence of chikungunya and o'nyong-nyong viruses in Senegal, West 2 Africa 3 4 Authors: Prince Baffour Tonto^{1,2}, Mouhamad Sy³, Ibrahima Mbaye Ndiaye³, Mariama 5 Toure³, Amy Gaye³, Mariama Aidara³, Amadou Moctar Mbaye³, Abdoulaye Kane Dia^{3,4}, Mamadou Alpha Diallo³, Jules Francois Gomis³, Mamadou Samba Yade³, Younous 6 7 Diedhiou³, Baba Dieye³, Khadim Diongue³, Mame Cheikh Seck³, Aida S. Badiane³, 8 Bobby Brooke Herrera^{1,2*}, Daouda Ndiaye³ 9 Affiliations: 10 1 Rutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA 11 12 2 Department of Medicine, Division of Allergy, Immunology, and Infectious Diseases 13 and Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical 14 School, New Brunswick, NJ, USA 15 3 International Research Training Center on Genomics and Health Surveillance 16 (CIGASS), Cheikh Anta Diop University, Dakar, 16477, Senegal 17 4 Laboratoire d'ecologie vectorielle et parasitaire 18 *Corresponding Author: BBH, bherrera@globalhealth.rutgers.edu 19 20 21 22

Abstract

23

24

28

35

Background

- 25 Arthritogenic alphaviruses such as chikungunya (CHIKV) and o'nyong-nyong (ONNV)
- viruses have shown capacity to cause widespread epidemics, with recurrent and
- 27 sporadic outbreaks occurring throughout sub-Saharan Africa.

Methods

- We analyzed the seroprevalence for CHIKV and ONNV in 470 non-febrile subjects from
- three regions in Senegal (Sindia, 2018; Thies, 2018; and Kedougou, 2022/2023) using
- 31 retrospective samples. We assessed the presence of anti-CHIKV IgG and neutralizing
- 32 titers against CHIKV and ONNV via enzyme-linked immunosorbent assay (ELISA) and
- 33 microneutralization tests, respectively, and determined risk factors of CHIKV and ONNV
- 34 exposure by binary logistic regression.

Results

- The overall seroprevalence of anti-CHIKV IgG was 24.89% (117/470). Regional
- 37 seroprevalences were 14.89% (14/94) in Sindia, 28.72% (27/94) in Thies, and 26.95%
- 38 (76/282) in Kedougou. Among CHIKV IgG-positive samples, 29.91% (35/117) and
- 39 39.32% (46/117) had neutralizing antibodies against CHIKV and ONNV, respectively. Of
- 40 the remaining samples, 20.51% (24/117) were equivocal and 10.26% (12/117) were
- 41 negative. Multivariate analysis showed that residence in Thies significantly increased
- 42 the likelihood of CHIKV infection (OR, 3.878; 95% CI: 0.783-19.205), whereas prior
- 43 malaria infection reduced it (aOR, 0.121; 95% CI: 0.049-0.300). Conversely, older age
- 44 (OR, 7.896; 95% CI: 1.500-41.556) and residence in Kedougou (OR, 3.180; 95% CI:

- 45 0.824-12.276) were significant risk factors for ONNV infection, with prior malaria
- infection also linked to higher ONNV susceptibility (aOR, 6.961; 95% CI: 2.456-19.732).

47 Conclusions

- 48 Our study confirms significant exposure to CHIKV and ONNV across Senegal,
- 49 underscoring the importance of ongoing surveillance and alphavirus testing among the
- 50 population.

51

52

54

55

56

57

58

59

60

61

62

63

64

65

66

Author summary

Arthritogenic alphaviruses, such as chikungunya (CHIKV) and o'nyong-nyong (ONNV)

viruses have the potential to cause widespread epidemics, with recurrent and sporadic

outbreaks occurring throughout sub-Saharan Africa. This study presents a retrospective

evaluation of CHIKV and ONNV seroprevalence among non-febrile subjects from three

regions in Senegal: Sindia, Thies, and Kedougou. Our analysis revealed regional

variation in alphavirus seroprevalence, with 29.91% of subjects exhibiting neutralizing

antibodies against CHIKV and 39.32% against ONNV. We identified that residence in

Thies was a risk factor for CHIKV, while residence in Kedougou, a history of malaria,

and older age were risk factors for ONNV. These findings suggest significant exposure

to CHIKV and ONNV across Senegal, underscoring the importance of ongoing

surveillance and alphavirus testing among the population.

Introduction

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

Arboviruses transmitted by mosquitoes pose a growing global health threat, significantly impacting morbidity and mortality. Among these, chikungunya (CHIKV) and o'nyong-nyong (ONNV) viruses are notable members of the alphavirus genus, recognized for their substantial effects on human health (1, 2). CHIKV, first isolated in Tanzania in 1952, has caused major outbreaks across Africa, Asia, and the Americas (3-5). Its transmission primarily involves *Aedes* mosquitoes, and its capacity for widespread dissemination was highlighted by the 2004 epidemic that originated in Kenya and rapidly extended to various regions, including the Indian Ocean islands and South and Southeast Asia (1, 5-7). By 2011, CHIKV reached the Western Hemisphere, spreading through the Caribbean and South America by 2014, resulting in hundreds of thousands of infections (8-10). ONNV, identified in Uganda in 1959, has caused significant epidemics primarily in East and West Africa, with major outbreaks recorded in the 1950s and early 1990s (11-13). Transmitted by *Anopheles* mosquitoes, ONNV remains largely confined to the African continent (6). The first major epidemic occurred from 1959 to 1962, affecting over 2 million people across East and West Africa (14, 15). A subsequent outbreak from 1996 to 1997 primarily impacted Uganda, Kenya, and Tanzania, with infection rates ranging from 45-68% (14, 16). Despite its geographical confinement, ONNV has been detected in travelers returning from endemic regions (17). Clinically, infections with CHIKV and ONNV are generally self-limiting but can present a spectrum of symptoms including fever, arthralgia, rash, headache, and malaise (18, 19). CHIKV is particularly associated with persistent arthralgia in patients

(20). Although ONNV is endemic to Africa, comprehensive data on its morbidity and mortality are limited due to inadequate surveillance. The clinical features of alphavirus infections closely resemble those caused by other pathogens including *Plasmodium* (malaria) or *Salmonella* (typhoid fever) species, which are endemic in many West African countries (21-26). This symptom overlap complicates diagnosis and can lead to underreporting of CHIKV and ONNV, as their symptoms may be misattributed to other febrile illnesses.

In West Africa, including Senegal, autochthonous cases of CHIKV have been reported since 1960, with periodic outbreaks continuing up to 2023 (27-31). Despite these occurrences, current data on the seroprevalence of CHIKV and ONNV in Senegal remains limited. This study aims to address this knowledge gap by investigating the seroprevalence of CHIKV and ONNV in Senegal. Given the antigenic similarities between these viruses, our approach focuses on using microneutralization assays to help differentiate between them to provide a more in-depth understanding of their prevalence. By enhancing our knowledge of the epidemiological landscape of CHIKV and ONNV in Senegal, we hope to inform public health strategies and contribute valuable insights into the broader context of arboviral transmission in West Africa.

Methods

Study Population and Ethics Statement

The samples included in our study were originally collected as part of malaria and non-malarial surveillance among residents of Thies, Sindia, and Kedougou, Senegal. Samples from Thies and Sindia were part of the surveillance of non-malarial

febrile illnesses, while samples from Kedougou were part of genomic surveillance of malaria. Informed consent was obtained from all subjects and/or their legal guardians for the initial sample collection as well as for its future use. All methods were performed in accordance with the guidelines and regulations set forth by the Declaration of Helsinki. The primary studies under which the samples and data were collected received ethical clearance from the CIGASS Institutional Review Board (IRB) (Protocol numbers: SEN15/46, 19300, and SEN14/49). All excess samples and corresponding data were banked and de-identified prior to the analyses.

CHIKV viral like particle (VLP) ELISA

CHIKV VLPs (20 ng per well; Native Antigen) were coated onto Nunc Maxisorp 96-well plates (ThermoFisher) overnight, followed by blocking (1X PBST, 1% BSA; ThermoFisher) for 1 hour, then washing (1X PBST three times) and incubation with primary antibodies for 2 hours (serum at 1:400 dilution) at room temperature. The plates were washed three times with 1X PBST and bound sera were reacted with secondary antibodies (anti-human IgG conjugated with horseradish peroxidase [HRP]; ThermoFisher), according to the manufacturer's instructions. The plates were washed three more times and allowed to develop with 1-Step TMB ELISA Substrate (ThermoFisher), according to the manufacturer's instructions. The OD at 450 nm was read with a reference wavelength of 650 nm using an ELISA reader (Diasource). We interpreted the ELISA assay as follows: 1) sample absorbance / negative control absorbance ≤ 1.5, negative; 2) sample absorbance / negative control absorbance > 1.5, positive.

Serum Microneutralization Assays

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

Microneutralization assays were performed to detect neutralizing antibodies against CHIKV and ONNV in samples that were IgG positive for CHIKV VLP. Sera were diluted in a two-fold series from 1:40 to 1:10,240 in PBS in a 96-well plate. For each dilution, contact was performed with 100 plaque forming units (PFU) of CHIKV (BEI Resources: NR-56523) or ONNV (BEI Resources: NR-51661) for one hour at 37°C in a 5% CO₂ incubator. The complexes were then added to Vero cells (ATCC) CCL-81, 1.3 x 10⁵ cells per well. After 3-4 days of incubation, the cytopathogenic effects were investigated by 0.2% crystal violet (SigmaAldrich) staining. After staining for 2-4 hours, the plates were washed with copious amounts of tap water. For negative controls, at least 3 alphavirus-naïve serum samples were used to incubate with CHIKV or ONNV prior to pipetting onto the Vero cells per plate. For positive controls, 100 PFU of CHIKV or ONNV without any contact with serum were placed on Vero cells in triplicate per plate. The neutralizing titer was defined as the inverse of the highest dilution resulting in an infectious reduction of 50%. A titer lower than 1:40 was considered as negative if cytopathogenic effects were not observed. Samples were considered as positive if the titer was ≥1:40, i.e., positive for ONNV if ONNV titers were at least two-fold higher than CHIKV titers, and CHIKV positive if CHIKV titers were at least four-fold higher than ONNV titers (32). The threshold was lower for ONNV than CHIKV because of the unique one-way cross-reactivity between CHIKV and ONNV, i.e., CHIKV antibodies are more likely to cross-react with ONNV antigens than ONNV antibodies with CHIKV antigens (33). All other results were interpreted as equivocal. 20 Senegalese serum

samples that were previously determined to be alphavirus-naïve, were used to validate the assay. Each assay used at least 4 alphavirus-naïve serum samples as negative controls.

Statistical Analysis

Categorical variables are represented as case counts and proportions. To estimate the association between seroprevalence of alphavirus and demographics factors, including age group, gender, city, and malaria status, univariate and multivariate binary logistic regression analyses were performed. The adjusted odd ratios of the independent variables were computed by adjusting for age and gender as confounding variables. Statistical analyses were conducted using IBM SPSS statistics software version 28. The map of Senegal, heatmap, and graph representing rates and percentages of CHIKV and ONNV neutralizing antibodies were generated using R version 4.3.2 and Prism version 10.2.0.

Results

A total of 470 samples collected from non-febrile subjects were included in the study. These samples were collected from three locations in Senegal: Sindia (n=94), Thies (n=94), and Kedougou (n=282) (Table 1). The samples from Sindia and Thies were malaria-negative by rapid diagnostic testing, whereas the samples from Kedougou were from subjects with malaria (Table 1). Participants' ages ranged from 6 months to 85 years, with an overall median age of 21 years. The study population was comprised of 44.89% females (n=211) (Table 1).

Table 1. Baseline characteristics and chikungunya virus (CHIKV) and o'nyong-

nyong virus (ONNV) serology

	Sindia	Thies	Kedougou	Total		
Characteristic and Serology	(n=94)	(n=94)	(n=282)	(N=470)		
Demographics						
Year(s) samples collected	2018	2018	2022-2023			
Median age (range)	24 (2-70)	20 (6 months- 69)	21 (2-85)	21 (6 months- 85)		
% Female (number)	41.49 (39)	54.25 (51)	42.91 (121)	44.89 (211)		
Malaria status, number (%)						
Positive	0 (0)	0 (0)	282 (100)	282 (60)		
Negative	94 (100)	94 (100)	0 (0)	188 (40)		
CHIKV VLP IgG, number (%)						
Positive	14 (14.89)	27 (28.72)	76 (26.95)	117 (24.89)		
Negative	80 (85.11)	67 (71.28)	206 (73.05)	353 (75.11)		
NT50, number/total (%)						
CHIKV	6/14 (42.86)	18/27 (66.67)	11/76 (14.47)	35/117 (29.91)		
ONNV	4/14 (28.57)	4/27 (14.81)	38/76 (50)	46/117 (39.32)		
Equivocal	4/14 (28.57)	5/27 (18.52)	15/76 (19.74)	24/117 (20.51)		
Negative	0 (0)	0 (0)	12/76 (15.79)	12/117 (10.26)		

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

Among the samples tested (n=470) for CHIKV VLP IgG antibodies, 117 tested positive, indicating an overall alphavirus seroprevalence of 24.89% (Table 1). Seroprevalence rates varied by location. Sindia had a rate of 14.89% (14/94), Thies had 28.72% (27/94), and Kedougou had 26.95% (76/282). In the serological analysis, a multivariate logistic regression revealed that subjects over 40 years old were more likely to have been exposed to an alphavirus, based on IgG reactivity to CHIKV VLP (OR, 2.100; 95% CI: 1.107-3.986) (S1 Table). Additionally, being a resident of Thies (OR, 2.384; 95% CI: 1.151-4.939) and Kedougou (OR, 5.591; 95% CI: 3.001-10.418) were associated with increased odds having been exposed to an alphavirus, with the highest risk observed in Kedougou (S1 Table). Furthermore, subjects with prior history of malaria were also more likely to have been exposed to an alphavirus (aOR, 3.465; 95% CI: 2.253-5.328) (S1 Table). The prevalence of neutralizing antibodies against CHIKV and ONNV varied by location in Senegal. The prevalence rates of CHIKV neutralizing antibodies were 42.86% (6/14) in Sindia, 66.67% (18/27) in Thies, and 14.47% (11/76) in Kedougou (Fig. 1A). For ONNV, the neutralizing antibody prevalence rates of were 28.57% (4/14) in Sindia, 14.81% (4/27) in Thies, and 50% (38/76) in Kedougou (Table 1, Fig. 1A). Overall, 29.91% (35/117) had neutralizing antibodies against CHIKV, 39.32% (46/117) had neutralizing antibodies against ONNV, 20.51% (24/117) were equivocal for both CHIKV and ONNV, and 10.26% (12/117) were negative (Table 1). Moreover, of the subjects with CHIKV neutralizing antibodies, 94.29% had cross-neutralizing antibodies against ONNV (Fig. 1B-C). However, of the subjects with ONNV neutralizing antibodies, only 53.33% had cross-neutralizing antibodies against CHIKV (Fig. 1B-C).




Fig. 1. Antibody neutralization against chikungunya (CHIKV) and o'nyong-nyong (ONNV) viruses in Senegal. A) Map depicts locations in Senegal (Sindia, Thies, and Kedougou) where samples were collected from non-febrile subjects. For each location, donut charts represent number and corresponding percentages of subjects with neutralizing antibodies against CHIKV and ONNV or equivocal and negative results. B) CHIKV virus-like particle IgG-positive samples were tested for neutralizing antibodies against CHIKV and ONNV. Colors depict the 50% neutralizing antibody titers (NT50), each row represents one individual, and each column is the titer to CHIKV or ONNV. C) The percentage of NT50-confirmed CHIKV or ONNV subjects with cross-neutralizing antibodies to the heterologous virus.

Multivariate logistic regression analyses revealed that subjects from Thies were more likely to be infected with CHIKV (OR, 3.878; 95% CI: 0.783-19.205) (Table 2). Conversely, being a resident of Kedougou (OR, 0.280; 95% CI: 0.074-1.054) and a prior history of malaria parasite (aOR, 0.121; 95% CI: 0.049-0.300) infection were associated with significantly lower odds of contracting CHIKV (Table 2). In contrast, subjects over 40 years of age were more likely to be infected with ONNV (OR, 7.896; 95% CI: 1.500-41.556) (Table 3). Additionally, being a resident of Kedougou (OR, 3.180; 95% CI: 0.824-12.276) and malaria infection (aOR, 6.961; 95% CI: 2.456-19.732) were associated with increased odds of contracting ONNV (Table 3).

Table 2. Risk factors for NT50-confirmed chikungunya virus (CHIKV) infections in

Senegal

255

256

CHIKV NT50-confirmed subjects						
Univariate				Multivariate		
Variable	OR (95% CI)	p value	aOR (95% CI)	p value	OR (95% CI)	p value
Age group						
≤ 20 years	Reference	0.255	Reference	0.268	Reference	0.688
21-40 years	1.07 (0.435- 2.635)		1.067 (0.433- 2.632)		1.571 (0.501- 4.930)	
> 40 years	2.529 (0.818- 7.826)		2.507 (0.802- 7.834)		1.471 (0.362- 5.978)	
Gender						
Male	Reference		Reference		Reference	
Female	1.167 (0.529- 2.572)	0.702	1.049 (0.467- 2.356)	0.907	1.022 (0.402- 2.597)	0.964
City						
Sindia	Reference	<0.001	Reference	<0.001	Reference	<0.001
Thies	3.167 (0.827- 12.126)		3.878 (0.783- 19.205)		3.878 (0.783- 19.205)	
Kedougou	0.237 (0.069- 0.815)		0.280 (0.074- 1.054)		0.280 (0.074- 1.054)	
Malaria statu	ıs					
No	Reference					
Yes	0.114 (0.046- 0.278)	<0.001	0.121 (0.049- 0.300)	<0.001	_	_

OR- Odd ratio; aOR- adjusted odd ratio for sex and age

Table 3. Risk factors for NT50-confirmed o'nyong-nyong virus (ONNV) infections

in Senegal

280

281

282

ONNV NT50-confirmed subjects							
	Univariate				Multi-variate		
Variable	OR (95% CI)	p value	aOR 9 (95% CI)	p value	OR 9 (95% CI)	p value	
Age group							
≤ 20 years	Reference	0.081	Reference	0.075	Reference	0.022	
21-40 years	s 2.396 (1.019-5.634)		2.423 (1.028-5.713)		2.356 (0.897-6.192)		
> 40 years	2.529 (0.818-7.826)		2.623 (0.837-8.224) 7.896 (1.500-41.556)		
Gender							
Male	Reference		Reference		Reference		
Female	0.882 (0.414-1.880)	0.746	0.835 (0.380-1.835)	0.653	0.872 (0.3730-2.038)0.751	
City							
Sindia	Reference	0.003	Reference	0.002	Reference	0.002	
Thies	0.313 (0.059-1.658)		0.212 (0.026-1.752)		0.212 (0.026-1.752)		
Kedougou	2.569 (0.738-8.941)		3.180 (0.824-12.276)	3.180 (0.824-12.276)	
Malaria status							
No	Reference						
Yes	4.992 (1.962-12.703)<0.001	6.961 (2.456-19.732)<0.001	-	-	

Discussion

This study provides novel insights into the seroprevalence of CHIKV and ONNV in Senegal, revealing significant regional differences that contribute to our understanding of arboviral dynamics in West Africa. Our findings indicate a substantial exposure to CHIKV and ONNV, with a detected anti-CHIKV IgG seroprevalence of 24.89% (117/470) among the study population (Table 1). This suggests an entrenched alphavirus presence that might be influencing public health without sufficient recognition or response.

The regional seroprevalences of anti-CHIKV IgG—14.89% in Sindia, 28.72% in Thies, and 26.95% in Kedougou—reflect notable geographical variability, consistent with previous studies across West Africa (Table 1). The significant variation between these regions highlights the role of local environmental and ecological factors in arbovirus transmission dynamics.

Our multivariate analysis underscores the influence of location, age, and malaria status on the risk of CHIKV and ONNV infection. Residents of Thies showed a three-fold increase in the likelihood of CHIKV infection compared to other regions, a finding that could be attributed to specific local vector ecology or differences in human activities that increase exposure to vectors (Table 2). Conversely, a history of malaria was associated with a reduced likelihood of CHIKV exposure, suggesting possible cross-immunity or behavioral adaptations that reduce exposure to vectors shared by both pathogens (Table 2). For ONNV, older age and residence in Kedougou significantly increased exposure risk, with Kedougou's unique environmental conditions potentially facilitating higher mosquito density and virus transmission (Table 3).

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

Furthermore, the presence of neutralizing antibodies in our sample cohort— 29.91% for CHIKV and 39.32% for ONNV—underscores ongoing virus circulation and potential for outbreaks (Fig. 1A). Notably, the high prevalence of ONNV neutralizing antibodies in Kedougou (50%) compared to other regions points to specific regional vulnerabilities, possibly driven by the overlapping mosquito vectors for malaria and ONNV (Fig. 1A). We also found that a high percentage (94.29%) of subjects with CHIKV neutralizing antibodies also had cross-neutralizing antibodies against ONNV (Fig. 1B-C). Conversely, a smaller proportion (53.33%) of those with ONNV neutralizing antibodies demonstrated cross-neutralization against CHIKV (Fig. 1B-C). These findings corroborate a directional bias in immune cross-reactivity, where CHIKV exposure might confer broader immunity, potentially impacting subsequent ONNV infection dynamics. This asymmetric cross-reactivity could also be due to structural similarities in the viral envelope proteins of CHIKV and ONNV, with CHIKV eliciting a broader neutralizing response (33). This phenomenon is crucial for diagnostic tests, which may need differentiation between past infections of these two viruses based on neutralizing antibody profiles. Moreover, understanding the mechanisms behind this differential cross-reactivity could guide vaccine strategies where a vaccine against one virus might offer partial protection against the other, hence optimizing the control measures for both viruses in regions where they co-circulate. The higher prevalence observed in older age groups for CHIKV supports the notion that cumulative exposure over time contributes to higher exposure rates. This demographic insight is crucial for developing targeted public health strategies, especially for vaccine deployment and vector control initiatives. The absence of a

similar age-related pattern for ONNV suggests different dynamics, potentially influenced by sporadic outbreaks rather than continuous exposure.

Limitations of our study include the retrospective nature of sample collection, which may not capture the most recent trends in virus circulation, and the absence of entomological data to directly correlate vector abundance with seroprevalence rates. Moreover, without concurrent clinical data, we cannot definitively link our serological findings to symptomatic disease cases, potentially underestimating the true burden of these infections. Also, IgG positivity does not necessarily reflect ongoing acute infections but generally is a sign of previous exposure to the virus (resolved infection). The insights into antibody cross-reactivity are essential for the interpretation of seroprevalence data in regions endemic to both viruses, as they could lead to overestimations of immunity against one virus due to past exposure to the other. This is particularly relevant in vaccine efficacy trials and in the evaluation of natural immunity in the population.

Conclusions drawn from our research illustrate the persistent circulation of CHIKV and ONNV in Senegal, necessitating sustained surveillance and public health preparedness to mitigate the impact of these and other arboviruses. The findings also emphasize the importance of ecological and demographic factors in shaping the epidemiology of these diseases, highlighting the need for comprehensive arbovirus control strategies that integrate vector management with community health initiatives. Future studies should aim to incorporate entomological and clinical data to provide a more holistic understanding of the transmission dynamics and to facilitate the development of targeted interventions, including vaccines and therapeutic measures.

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

Acknowledgements We would like to thank Rutgers Global Health Institute, Rutgers Robert Wood Johnson Medical School, and the Child Health Institute of New Jersey. **Conflicts of Interest** BBH is a co-founder of Mir Biosciences, Inc., a biotechnology company that develops diagnostics and vaccines for infectious diseases, cancer, and autoimmunity. **Author Contributions** Conceptualization: BBH Data curation: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD, MCS, ASB, BBH, DN Formal analysis: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD, MCS, ASB, BBH, DN Funding acquisition: BBH, DN Investigation: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD, MCS, ASB, BBH, DN Methodology: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD, MCS, ASB, BBH, DN Project administration: BBH, DN

- 374 Resources: BBH, DN
- 375 Software: PBT, MS, BBH
- 376 Supervision: BBH, MS, DN
- Validation: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,
- 378 MCS, ASB, BBH, DN
- Visualization: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,
- 380 MCS, ASB, BBH, DN
- 381 Writing original draft: PBT, BBH
- Writing review & editing: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY,
- 383 YD, BD, KD, MCS, ASB, BBH, DN

References

384

- 1. Pezzi L, LaBeaud AD, Reusken CB, Drexler JF, Vasilakis N, Diallo M, et al.
- 387 GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 2:
- 388 Epidemiological distribution of o'nyong-nyong virus. Antiviral Res. 2019;172:104611.
- 389 2. Zaid A, Burt FJ, Liu X, Poo YS, Zandi K, Suhrbier A, et al. Arthritogenic
- 390 alphaviruses: epidemiological and clinical perspective on emerging arboviruses. Lancet
- 391 Infect Dis. 2021;21(5):e123-e33.
- 392 3. Renault P, Balleydier E, D'Ortenzio E, Baville M, Filleul L. Epidemiology of
- 393 Chikungunya infection on Reunion Island, Mayotte, and neighboring countries. Med Mal
- 394 Infect. 2012;42(3):93-101.
- 395 4. Wahid B, Ali A, Rafigue S, Idrees M. Global expansion of chikungunya virus:
- mapping the 64-year history. Int J Infect Dis. 2017;58:69-76.

- 397 5. Zeller H, Van Bortel W, Sudre B. Chikungunya: Its History in Africa and Asia and
- 398 Its Spread to New Regions in 2013-2014. J Infect Dis. 2016;214(suppl 5):S436-S40.
- 399 6. Pezzi L, Diallo M, Rosa-Freitas MG, Vega-Rua A, Ng LFP, Boyer S, et al.
- 400 GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 5:
- 401 Entomological aspects. Antiviral Res. 2020;174:104670.
- 402 7. Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi LS, et al.
- Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya,
- 404 October 2004. Am J Trop Med Hyg. 2008;78(2):333-7.
- 405 8. Fischer M, Staples JE, Arboviral Diseases Branch NCfE, Zoonotic Infectious
- 406 Diseases CDC. Notes from the field: chikungunya virus spreads in the Americas -
- 407 Caribbean and South America, 2013-2014. MMWR Morb Mortal Wkly Rep.
- 408 2014;63(22):500-1.
- 409 9. Manzoor KN, Javed F, Ejaz M, Ali M, Mujaddadi N, Khan AA, et al. The global
- 410 emergence of Chikungunya infection: An integrated view. Rev Med Virol.
- 411 2022;32(3):e2287.
- 412 10. Teixeira MG, Andrade AM, Costa Mda C, Castro JN, Oliveira FL, Goes CS, et al.
- East/Central/South African genotype chikungunya virus, Brazil, 2014. Emerg Infect Dis.
- 414 2015;21(5):906-7.
- 415 11. Corbet PS, Williams MC, Gillett JD. O'Nyong-Nyong fever: an epidemic virus
- 416 disease in East Africa. IV. Vector studies at epidemic sites. Trans R Soc Trop Med Hyg.
- 417 1961;55:463-80.

- 418 12. Williams MC, Woodall JP, Corbet PS, Gillett JD. O'nyong-Nyong Fever: An
- 419 Epidemic Virus Disease in East Africa. 8. Virus Isolations from Anopheles Mosquitoes.
- 420 Trans R Soc Trop Med Hyg. 1965;59:300-6.
- 421 13. Lanciotti RS, Ludwig ML, Rwaguma EB, Lutwama JJ, Kram TM, Karabatsos N,
- et al. Emergence of epidemic O'nyong-nyong fever in Uganda after a 35-year absence:
- 423 genetic characterization of the virus. Virology. 1998;252(1):258-68.
- 424 14. Rezza G, Chen R, Weaver SC. O'nyong-nyong fever: a neglected mosquito-
- borne viral disease. Pathog Glob Health. 2017;111(6):271-5.
- 426 15. Williams MC, Woodall JP, Gillett JD. O'nyong-Nyong Fever: An Epidemic Virus
- Diesease in East Africa. Vii. Virus Isolations from Man and Serological Studies up to
- 428 July 1961. Trans R Soc Trop Med Hyg. 1965;59:186-97.
- 429 16. Kiwanuka N, Sanders EJ, Rwaguma EB, Kawamata J, Ssengooba FP, Najjemba
- R, et al. O'nyong-nyong fever in south-central Uganda, 1996-1997: clinical features and
- validation of a clinical case definition for surveillance purposes. Clin Infect Dis.
- 432 1999;29(5):1243-50.
- 433 17. Tappe D, Kapaun A, Emmerich P, Campos Rde M, Cadar D, Gunther S, et al.
- O'nyong-nyong virus infection imported to Europe from Kenya by a traveler. Emerg
- 435 Infect Dis. 2014;20(10):1766-7.
- 436 18. Johnson BK. O'nyong-nyong virus disease. Arboviruses: CRC Press; 2019. p.
- 437 **217-24**.
- 438 19. Kucharz EJ, Cebula-Byrska I. Chikungunya fever. Eur J Intern Med.
- 439 2012;23(4):325-9.

- 440 20. Schilte C, Staikovsky F, Couderc T, Madec Y, Carpentier F, Kassab S, et al.
- 441 Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal
- study. PLoS neglected tropical diseases. 2013;7(3):e2137.
- 443 21. Al-Emran HM, Eibach D, Krumkamp R, Ali M, Baker S, Biggs HM, et al. A
- 444 multicountry molecular analysis of Salmonella enterica serovar Typhi with reduced
- susceptibility to ciprofloxacin in sub-Saharan Africa. Clinical Infectious Diseases.
- 446 2016;62(suppl 1):S42-S6.
- 447 22. Badiane AS, Ngom B, Ndiaye T, Cunningham D, Campbell J, Gaye A, et al.
- Evidence of Plasmodium vivax circulation in western and eastern regions of Senegal:
- implications for malaria control. Malaria Journal. 2024;23(1):149.
- 450 23. Diallo A, Sié A, Sirima S, Sylla K, Ndiaye M, Bountogo M, et al. An
- 451 epidemiological study to assess Plasmodium falciparum parasite prevalence and
- malaria control measures in Burkina Faso and Senegal. Malaria journal. 2017;16:1-12.
- 24. Diallo M, Diongue K, Diagne G, Seck M, Ndiaye M, Dièye B, et al. Plasmodium
- ovale wallikeri and Plasmodium ovale curtisi Malaria in Senegal in 2016. Bulletin de la
- 455 Société de pathologie exotique. 2017;110:286-90.
- 456 25. Dromigny J-A, Perrier-Gros-Claude J-D. Antimicrobial resistance of Salmonella
- enterica serotype Typhi in Dakar, Senegal. Clinical infectious diseases. 2003;37(3):465-
- 458 6.
- 459 26. Harrois D, Breurec S, Seck A, Delauné A, Le Hello S, de La Gandara MP, et al.
- 460 Prevalence and characterization of extended-spectrum β-lactamase-producing clinical
- Salmonella enterica isolates in Dakar, Senegal, from 1999 to 2009. Clinical
- 462 Microbiology and Infection. 2014;20(2):O109-O16.

- 27. Dieng I, Sadio BD, Gaye A, Sagne SN, Ndione MHD, Kane M, et al. Genomic
- characterization of a reemerging Chikungunya outbreak in Kedougou, Southeastern
- 465 Senegal, 2023. Emerg Microbes Infect. 2024;13(1):2373308.
- 466 28. Pistone T, Ezzedine K, Boisvert M, Receveur MC, Schuffenecker I, Zeller H, et
- 467 al. Cluster of chikungunya virus infection in travelers returning from Senegal, 2006. J
- 468 Travel Med. 2009;16(4):286-8.
- 469 29. Roche S, Robin Y. [Human infections by Chikungunya virus in Rufisque
- 470 (Senegal), October-November, 1966]. Bull Soc Med Afr Noire Lang Fr. 1967;12(3):490-
- 471 6.

484

- 472 30. Saluzzo J, Cornet M, Digoutte J. Outbreak of a Chikungunya virus epidemic in
- western Senegal in 1982. Dakar medical. 1983;28(3):497-500.
- 474 31. Sow A, Faye O, Diallo M, Diallo D, Chen R, Faye O, et al. Chikungunya Outbreak
- in Kedougou, Southeastern Senegal in 2009-2010. Open Forum Infect Dis.
- 476 2018;5(1):ofx259.
- 477 32. LaBeaud AD, Banda T, Brichard J, Muchiri EM, Mungai PL, Mutuku FM, et al.
- High rates of o'nyong nyong and Chikungunya virus transmission in coastal Kenya.
- 479 PLoS Negl Trop Dis. 2015;9(2):e0003436.
- 480 33. Hoze N, Diarra I, Sangare AK, Pastorino B, Pezzi L, Kouriba B, et al. Model-
- 481 based assessment of Chikungunya and O'nyong-nyong virus circulation in Mali in a
- serological cross-reactivity context. Nat Commun. 2021;12(1):6735.

Supporting information

- 485 S1 Table. Risk factors for alphavirus exposure (chikungunya virus virus-like
- particle lgG+) in Senegal. OR- Odd ratio; aOR- adjusted odd ratio for sex and age.